Plain-English translation of NCT07078994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called BCD-261 to see if it can help people with moderate to severe Crohn's disease feel better. Researchers will compare different doses of the medication against a placebo (dummy treatment) to find the best dose that works safely. The medication is designed to reduce inflammation in the intestines and improve symptoms.
Many people with Crohn's disease don't respond well enough to current treatments, or their disease comes back after they stop taking medications. This trial exists to find out whether this new treatment can help people whose Crohn's disease has been hard to control with existing therapies.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly over several months for check-ups, blood tests, and endoscopy procedures to measure how well the medication is working. You will be randomly assigned to receive either the new medication at one of several doses or a placebo for the first 12 weeks (the 'induction' phase), then continue for a longer maintenance period. If you receive the placebo, you will be switched to the active medication after the initial phase so you can benefit from the treatment.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Russia